Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Common Equity (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Common Equity for 7 consecutive years, with $292.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 30.71% to $292.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $292.5 million through Dec 2025, down 30.71% year-over-year, with the annual reading at $292.5 million for FY2025, 30.71% down from the prior year.
  • Common Equity hit $292.5 million in Q4 2025 for Allogene Therapeutics, down from $315.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.1 billion in Q1 2021 to a low of $292.5 million in Q4 2025.
  • Historically, Common Equity has averaged $628.9 million across 5 years, with a median of $586.3 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 76.38% in 2021 and later plummeted 33.1% in 2025.
  • Year by year, Common Equity stood at $925.2 million in 2021, then fell by 27.92% to $666.9 million in 2022, then fell by 23.19% to $512.2 million in 2023, then fell by 17.58% to $422.2 million in 2024, then tumbled by 30.71% to $292.5 million in 2025.
  • Business Quant data shows Common Equity for ALLO at $292.5 million in Q4 2025, $315.3 million in Q3 2025, and $344.6 million in Q2 2025.